Education and Professional Standing
Dr Meyre completed a PhD in quantitative plant genetics in France. Since 2001, he is working on the elucidation of the genetic bases of obesity and type 2 diabetes. He published the first family-based genome-wide scan for childhood obesity, which identified a significant region for linkage on chromosome 6q. He completed the first successful positional cloning effort for childhood obesity, which identified the positional candidate gene ENPP1. He participated to the identification of FTO, the major susceptibility gene for polygenic obesity. David Meyre was part of the team who published the first genome-wide association study (GWAS) in complex diseases in 2007. In 2009, David Meyre published the first genome-wide association study of extreme obesity in the French population and identified four novel susceptibility-loci. He also conducted the first genome-wide association meta-analysis for early-onset extreme obesity in German and French populations, leading to the identification of two novel childhood obesity predisposing loci. In 2010, he contributed to the identification of the first structural variant (a 600 bp deletion located on the chromosome 16p11.2) associated to highly penetrant forms of severe obesity. In 2012, he identified the third more common form of monogenic obesity (PCSK1 partial deficiency) and proved an important role of the lipid sensor GPR120 in human obesity. He also participated to an international meta-analysis effort involving more than 20,000 kids that identified nine loci contributing to childhood obesity.
With 96 articles published up to date (25 appeared in first-rank journals such as Nature, Science, Nature Genetics...), Dr Meyre is an internationally recognized expert in genetic epidemiology of metabolic diseases. His current research interests include 1) the identification of novel susceptibility genes using high-throughput sequencing / genotyping approaches in populations representative of the worldwide ethnic background 2) a better understanding of the physiological and molecular mechanisms underlying the development of metabolic diseases 3) the interactions between genes and specific environmental exposures 4) the usefulness of genetic information in clinical applications (prevention and care).